Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29895897 | 1.00 | EGFR (0.54) | EGFRCYP2D6CYP3A4CYP2C9STING1 | |
| SCHEMBL17121775 | 1.00 | EGFR (0.54) | EGFRCYP2D6CYP3A4CYP2C9STING1 | |
| SCHEMBL19025015 | 0.93 | EGFR (0.57) | EGFRCYP2D6CYP3A4CYP2C9STING1 | |
| SCHEMBL19025016 | 0.93 | EGFR (0.57) | EGFRCYP2D6CYP3A4CYP2C9STING1 | |
| SCHEMBL29816724 | 0.90 | EGFR (0.57) | EGFRCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL17121613 | 0.90 | EGFR (0.57) | EGFRCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL28827665 | 0.90 | EGFR (0.57) | EGFRCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL17121619 | 0.90 | EGFR (0.56) | EGFRCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL17121681 | 0.89 | EGFR (0.56) | EGFRCYP2D6CYP3A4CYP2C9ACKR3 | |
| SCHEMBL28827667 | 0.89 | EGFR (0.56) | EGFRCYP2D6CYP3A4CYP2C9ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114989140-A | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | 卡佩拉医疗公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114940673-A | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | 卡佩拉医疗公司 | 2022-08-26 | — | — | CN | disclosed |